Processa Pharmaceuticals, Inc. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Form 8-K filed 2026-08-04 reports Item 5.02 (director/officer changes and compensation) and Item 5.07 (shareholder vote submission). No specific names, dollar amounts, dates of departure, or compensation figures are provided in the available filing metadata. The actual substantive details are contained in the full 8-K document but are not extracted in this summary.
Why this rating
Director/officer changes are routine disclosures. Without concrete details (names, amounts, roles), impact cannot be assessed. At $8.1M market cap, most personnel changes are moderate unless involving majority shareholder/CEO loss.
Extracted items
- 5.02 exec change
- 5.07 shareholder vote
- 9.01 exhibits
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.